Engrail Therapeutics, a San Diego, CA-based developer of – medicines to transform the lives of patients with life-limiting diseases of the nervous system, closed a $32m Series A financing round.
The round was led by Nan Fung Life Sciences (NFLS). The company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.
Founded in 2019 and led by Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics combines biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. The company adopts a ‘science-first’ approach that begins with a thorough biological understanding of disease and rational therapeutic targeting, enabling it to identify compounds. This, combined with a comprehensive view of clinical development strategy, regulatory considerations, intellectual property and optimal commercial positioning, allows Engrail to acquire high-quality assets with a lower-risk path to market. The company expects to acquire assets with validated mechanisms, catalyzing a diverse portfolio of therapies to treat diseases of the nervous system. Its flexible transaction model includes licensing, co-development and company acquisitions.